 Name: ___          Unit No:  ___  Admission Date: ___       Discharge Date:  ___  Date of Birth: ___       Sex:  M  Service: MEDICINE  Allergies: Bactrim  Attending: ___.  Chief Complaint: Fever  Major Surgical or Invasive Procedure: Bone Marrow Biopsy (___)

 History of Present Illness: Mr. ___ is an ___ male with MDS transformed to AML on decitabine/venetoclax, diastolic congestive heart failure, polyarticular pseudogout, and myasthenia ___ (on chronic prednisone) who presents with fever.

Patient reports that he developed chills earlier this evening with fever to 100.0. Had one loose stool. He denies recent travel. He denies sick contacts. He was seen in clinic yesterday and had blood and platelet transfusions.

On arrival to the ED, initial vitals were 102.7 105 137/81 16 96% RA. Exam was unremarkable. Labs were notable for WBC 0.9 (ANC 170), H/H 7.6/23.7, Plt 13, Na 137, K 4.2, BUN/Cr ___, and lactate 2.7. Blood cultures were sent. CXR was negative for pneumonia. Patient was given cefepime. Unclear if was given Tylenol (received 1g per wife but not ordered in POE or documented in ___. Prior to transfer vitals were 102.8 84 132/86 16 95% RA.

On arrival to the floor, patient reports feeling weak. He has no acute complaints. He denies any viral symptoms. He denies headache, vision changes, dizziness/lightheadedness, weakness/numbnesss, shortness of breath, cough, hemoptysis, chest pain, palpitations, abdominal pain, nausea/vomiting, hematemesis, hematochezia/melena, dysuria, hematuria, and new rashes.

REVIEW OF SYSTEMS: A complete 10-point review of systems was performed and was negative unless otherwise noted in the HPI.  Past Medical History: PAST ONCOLOGIC HISTORY: - ___: Evaluated by Dr. ___ Atrius ___ for new macroytic anemia. - ___: Bone marrow biopsy reveals hypercellular bone marrow with myeloid predominant trilineage hematopoiesis, abnormal megakaryocytes and mild erythroid and myeloid dysplasia, suspicious for involvement by an evolving myelodysplastic syndrome. R-IPSS score 2.0 (low risk). Initiates PRBC transfusions as needed. - ___: Begins darbepoetin 300 mcg twice weekly, increased to 500 mcg twice weekly after little response. - ___: Repeat bone marrow biopsy reveals dysplastic myeloid erythroid and megakaryocytes. There was not an increased number of blasts in the marrow though he does have occasional blasts in his peripheral blood smears. His cytogenetics were entirely normal; he was 46 XY karyotype. The usual MDS panel was performed and was negative by fish. - ___: C1D1 azacitidine (only receives 4 doses). - ___: C2D1 azacytidine. - ___: C3D1 azacitidine (only receives 2 doses). - ___: C4D1 azacitidine (only receives 3 doses). - ___: Begins lenalidomide 10 mg daily. Held intermittently for fever and pseudogout. - ___: Lenalidomide held on a permanent basis. - ___: Develops 1-5% peripheral blasts. - ___: C1D1 decitabine 20 mg/m2 x 5 days. - ___: C2D1 decitabine 20 mg/m2 x 5 days. - ___: Repeat bone marrow aspiration and biopsy reveals hypercellular bone marrow with involvement by known MDS, 5% blasts by immunohistochemistry and flow cytometry, normal male karyotype, FISH negative for common MDS abnormalities, molecular analysis with mutations in TET2, KIT, EZH2, NF1, STAG2, and SETD2. - ___: C3D1 decitabine 20 mg/m2 x 5 days. - ___: C4D1 decitabine 20 mg/m2 x 5 days. - ___: Repeat bone marrow aspiration and biopsy reveals hypercellular myeloid predominant marrow with trilineage dysplasia and increased blasts ___ by morphology and flow cytometry, respectively), normal male karyotype, molecular analysis with mutations in TET2, STAG2, EZH2, SETD2, KIT, and NF1. - ___: C5D1 decitabine 20 mg/m2 x 5 days. - ___: C6D1 decitabine 20 mg/m2 x 4 days(abbreviated length due to pt travel plans). - ___: C7D1 decitabine 20 mg/m2 x 5 days. - ___: C8D1 decitabine 20 mg/m2 x 4 days. - ___: C9D1 decitabine 20 mg/m2 x 5 days. - ___: C10D1 decitabine 20 mg/m2 x 5 days. - ___: Right port removal due to port being exposed. New left chest port placement. - ___: Admission for fever and cough, diagnosed with community-acquired pneumonia or consolidation seen on chest CT. improvement with cefepime, transition to Levaquin to complete 7-day course on ___. Viral PCR panel negative from NP swab. - ___: C11D1 decitabine 20 mg/m2 x 5 days. - ___: Peripheral blasts persistently ___. - ___: Surveillance bone marrow biopsy reveals a hypercellular bone marrow with involvement by AML with MDS-related changes. Karytotype and AML FISH panels are normal. Molecular sequencing remains PENDING. - ___: C1D1 Decitabine/Venetoclax. - ___: Initiates Venetoclax 100 mg daily. - ___: Increases Venetoclax to 200 mg daily (target dose).

PAST MEDICAL HISTORY: - Myelodysplastic Syndrome with evolution to Acute Myelogenous Leukemia, as above. - Diastolic Congestive Heart Failure - Polyarticular Pseudogout - Myasthenia ___ (Diagnosed about ___ years ago. Presented with right eye closure (ptosis), tongue swelling. The symptoms occur very infrequently. Followed by Dr. ___ at ___). - Hypertension - Hypothyroidism - Vitamin D Deficiency - Colon Polyps - Intervertebral Lumbar Disc Disorder with myelopathy, lumbar region - Seborrheic Keratosis - Actinic Keratosis - Basal Cell Carcinoma - Squamous Cell Carcinoma, followed by dermatologist Dr. ___ at ___ in ___ - Venous Tributary (branch) Occlusion of Retina - s/p hernia repair x ___ - s/p right knee replacement  Social History: ___ Family History: Father-rheumatic fever ___ disease Maternal grandmother-colon cancer No family history of hematologic disorder  Physical Exam: ADMISSION PHYSICAL EXAM: VS: Temp 102.3, BP 115/57, HR 83, RR 18, O2 sat 95% RA. GENERAL: Very pleasant man, in no distress, lying in bed comfortably. HEENT: Anicteric, PERLL, OP clear, temporal wasting. CARDIAC: RRR, normal s1/s2, no m/r/g. LUNG: Appears in no respiratory distress, clear to auscultation bilaterally, no crackles, wheezes, or rhonchi. ABD: Soft, non-tender, non-distended, positive bowel sounds. EXT: Warm, well perfused, no lower extremity edema. NEURO: A&Ox3, good attention and linear thought, gross strength and sensation intact. SKIN: No significant rashes. ACCESS: Left chest wall port without erythema.

DISCHARGE PHYSICAL EXAM ___ 0642 Temp: 97.8 PO BP: 152/66 HR: 54 RR: 16 O2 sat: 97% O2 delivery: RA GENERAL: Older man in NAD HEENT: NCAT, sclerae anicteric, oropharynx clear, MMM CARDIAC: RRR, normal s1/s2, no m/r/g LUNG: Decreased breath sounds at L base (comparable to prior), otherwise CTAB, no increased work of breathing ABD: Soft, non-tender, non-distended, normoactive BS EXT: Warm, DP pulses 2+ bilaterally, no edema NEURO: A&Ox3, good attention and linear thought SKIN: No significant rashes BACK: No evidence of hematoma or infection at biopsy site ACCESS: Left chest wall port without erythema  Pertinent Results: ADMISSION LABS: ___ 10:35PM BLOOD WBC: 0.9* RBC: 2.71* Hgb: 7.6* Hct: 23.7* MCV: 88 MCH: 28.0 MCHC: 32.1 RDW: 14.2 RDWSD: 44.___* ___ 10:35PM BLOOD Neuts: 19* Lymphs: 65* Monos: 7 Eos: 7 Baso: 0 Atyps: 1* Myelos: 1* AbsNeut: 0.17* AbsLymp: 0.59* AbsMono: 0.06* AbsEos: 0.06 AbsBaso: 0.00* ___ 10:35PM BLOOD Glucose: 105* UreaN: 29* Creat: 1.1 Na: 137 K: 4.2 Cl: 101 HCO3: 23 AnGap: 13 ___ 10:49PM BLOOD Lactate: 2.7*

PERTINENT STUDIES: ___ Imaging CT SINUS/MANDIBLE/MAXIL Moderate mucosal thickening within the right sphenoid sinus, mildly progressed compared to prior. Mild mucosal thickening within the posterior ethmoid air cells and right maxillary sinus, unchanged. No air-fluid levels. 

___HEST W/CONTRAST Findings suggestive of left lower lobe pneumonia associated to small ipsilateral pleural effusion. The location in the posterior basal segment of the left lower lobe impairs evaluation of this consolidation with single AP radiographs. Recommend follow up in ___ weeks with either PA and lateral radiographs or chest CT. 

___BD & PELVIS WITH CO No evidence of acute abnormality involving the abdomen or pelvis.

___ TTE Normal left ventricular wall thickness and biventricular cavity sizes and regional/global systolic function (EF 60%). Mild aortic valve stenosis. Mild mitral regurgitation. Mild-moderate pulmonary artery systolic hypertension. Compared with the prior TTE (images reviewed) of ___, the severity of mitral regurgitation, tricuspid regurgitattion and estimated PA systolic pressure are all now lower and regional/global left ventricular systolic function is now improved/normal.

PERTINENT MICROBIOLOGY: No growth to date on all blood and urine cultures prior to discharge.

PATHOLOGY: Urine, voided: NEGATIVE FOR HIGH-GRADE UROTHELIAL CARCINOMA.

BONE MARROW BIOPSY IMMUNOPHENOTYPING: Diagnostic immunophenotypic features of involvement by leukemia are not seen in this specimen. Correlation with clinical, morphologic (see separate pathology report ___, cytogenetics studies (see separate cytogenetics report ___) and other ancillary findings is recommended. Flow cytometry immunophenotyping may not detect all abnormal populations due to topography, sampling or artifacts of sample preparation. 

CYTOGENETIC DIAGNOSIS: 46,XY[20] Normal male karyotype.

DISCHARGE LABS: ___ 12:00AM BLOOD WBC-0.9* RBC-2.38* Hgb-7.1* Hct-21.6* MCV-91 MCH-29.8 MCHC-32.9 RDW-13.9 RDWSD-46.1 Plt Ct-9* ___ 12:00AM BLOOD Neuts-10* Lymphs-82* Monos-4* Eos-0* Baso-0 Atyps-3* Myelos-1* AbsNeut-0.09* AbsLymp-0.77* AbsMono-0.04* AbsEos-0.00* AbsBaso-0.00* ___ 06:30AM BLOOD Plt Ct-24* ___ 12:00AM BLOOD Glucose-125* UreaN-26* Creat-1.0 Na-138 K-4.1 Cl-104 HCO3-25 AnGap-9* ___ 12:00AM BLOOD ALT-65* AST-49* LD(LDH)-176 AlkPhos-82 TotBili-0.2 ___ 12:00AM BLOOD Calcium-8.4 Phos-3.1 Mg-1.8 UricAcd-2.8*  Brief Hospital Course: Mr. ___ is an ___ male with MDS transformed to AML on decitabine/venetoclax, diastolic congestive heart failure, polyarticular pseudogout, and myasthenia ___ (on chronic prednisone) who presented with fever. He was found to have a LLL PNA on CT chest and completed 8 days of cefepime. 

TRANSITIONAL ISSUES:

[ ] F/u bone marrow biopsy report [ ] Patient started on posaconazole this admission, consider additional QTc monitoring by EKG [ ] Venetoclax dose-reduced to 70 given initiation of posaconazole [ ] Consider re-checking renal function, electrolytes given inpatient initiation of lisinopril 10MG, consider additional uptitration based on BP [ ] Consider repeat TTE if having significant weight gain or evidence of volume overload

ACUTE ISSUES: #Febrile Neutropenia #LLL PNA Seen on CT chest, initially started on vanc/cefepime, vanc dc'd after MRSA swab negative. Fungal markers were notable for positive B-D-glucan, however as the patient had improved clinically, anti-fungal therapy was not initiated. Completed 8 days of cefepime, discontinued on ___ and transitioned to levofloxacin for prophylaxis. Patient subsequently remaining afebrile, clinically well without symptoms of infection for >48H off cefepime prior to discharge.

# AML C12 Decitabine, Venetoclax newly initiated this cycle. D1 = ___. Venetoclax held on admission. Prophylactic fluc switched to posaconazole, other home prophylactic medications continued. Given new posaconazole, home venetoclax dose-reduced to 70MG. QTc monitored by EKG while on venetoclax, levofloxacin, posaconazole. ANC remained suppressed while inpatient. Bone marrow biopsy performed on ___, with core showing hypercellularity but w/o significant blasts on prelim; IHC pending at discharge. 

#HFpEF On review of weights, appears patient gained ~10 lbs since last clinic appointment, likely in setting of significant IV inputs. Required intermittent PO lasix 20mg for diuresis. Patient subsequently euvolemic without evidence of volume overload for 4 days off Lasix prior to discharge.

#HTN BP elevated to 170s on ___. Started lisinopril 10MG on ___, pressures improved.

CHRONIC ISSUES: #h/o CDiff infection Was started on PO Vanc BID due to h/o C Diff infection. Has had one instance of this on review of records here. As such, we will discontinue prophylaxis and monitor bowel movements to determine recurrence. No episodes of diarrhea or c/f C. diff this admission.

# Anemia/Thrombocytopenia: Secondary to AML and recent chemotherapy. Patient required intermittent platelet transfusions approximately every other day while admitted. Patient and family able to come in for frequent transfusions as outpatient.

# Myasthenia ___ Home steroid dose was doubled in setting of acute infection, then tapered back to home 7.5MG prior to discharge. Continued PPI for GI prophylaxis.

# Hypothyroidism Continued home levothyroxine.  Medications on Admission: The Preadmission Medication list is accurate and complete. 1. Acetaminophen ___ mg PO BID:PRN Pain - Mild 2. Acyclovir 400 mg PO Q12H 3. Atovaquone Suspension 1500 mg PO DAILY 4. Fluconazole 200 mg PO Q24H 5. Levothyroxine Sodium 50 mcg PO DAILY 6. Magnesium Oxide 400 mg PO TID 7. Multivitamins 1 TAB PO DAILY 8. Omeprazole 20 mg PO DAILY 9. Calcium 600 + D(3) (calcium carbonate-vitamin D3) 600 mg(1,500mg) -400 unit oral DAILY 10. Senna 8.6 mg PO QHS 11. Psyllium Powder 1 PKT PO DAILY 12. PredniSONE 7.5 mg PO DAILY 13. Venetoclax 200 mg PO DAILY 14. Allopurinol ___ mg PO DAILY 

 Discharge Medications: 1. Levofloxacin 500 mg PO Q24H RX *levofloxacin 500 mg 1 tablet(s) by mouth once a day Disp #*30 Tablet Refills:*0 2. Lisinopril 10 mg PO DAILY RX *lisinopril 10 mg 1 tablet(s) by mouth once a day Disp #*30 Tablet Refills:*0 3. Posaconazole Delayed Release Tablet 300 mg PO DAILY  4. Venetoclax 70 mg PO DAILY RX *venetoclax [Venclexta] 50 mg 1 tablet(s) by mouth once a day Disp #*30 Tablet Refills:*0 RX *venetoclax [Venclexta] 10 mg 2 tablet(s) by mouth once a day Disp #*60 Tablet Refills:*0 5. Acetaminophen ___ mg PO BID:PRN Pain - Mild  6. Acyclovir 400 mg PO Q12H  7. Allopurinol ___ mg PO DAILY  8. Atovaquone Suspension 1500 mg PO DAILY  9. Calcium 600 + D(3) (calcium carbonate-vitamin D3) 600 mg(1,500mg) -400 unit oral DAILY  10. Levothyroxine Sodium 50 mcg PO DAILY  11. Magnesium Oxide 400 mg PO TID  12. Multivitamins 1 TAB PO DAILY  13. Omeprazole 20 mg PO DAILY  14. PredniSONE 7.5 mg PO DAILY  15. Psyllium Powder 1 PKT PO DAILY  16. Senna 8.6 mg PO QHS 

 Discharge Disposition: Home  Discharge Diagnosis: PRIMARY DIAGNOSES #Febrile Neutropenia #Pneumonia

SECONDARY DIAGNOSES #AML #HFpEF #Myasthenia ___ #HTN #ypothyroidism

 Discharge Condition: Mental Status: Clear and coherent. Level of Consciousness: Alert and interactive. Activity Status: Ambulatory - Independent.

 Discharge Instructions: Dear ___

___ you for coming to ___ for your care. Please read the following instructions carefully:

WHY WAS I ADMITTED TO THE HOSPITAL? - You were admitted to the hospital because you had a fever while your blood counts were low.

WHAT WAS DONE FOR ME WHILE I WAS HERE? - You were found to have a pneumonia - You were given antibiotics for your infection - We started you on blood pressure medications - You had a bone marrow biopsy - You were started on new medications to prevent infection in the setting of neutropenia

WHAT DO I NEED TO DO WHEN I LEAVE THE HOSPITAL? - Please take your medications as prescribed - Please keep your follow-ups as listed below - If you develop a fever of 100.4 or greater, please call your oncologist and seek urgent medical attention  Followup Instructions: ___ 